 G21 |
 |
Secondary parkinsonism  |
| |
| Excludes1 |
Huntington's disease (G10)
neurocognitive disorder with Lewy bodies (G31.83)
Shy-Drager syndrome (G90.3)
syphilitic Parkinsonism (A52.19)
|
|
| |
 G21.0 |
|
Malignant neuroleptic syndrome |
| |
|
|
| |
| G21.1 |
|
Other drug-induced secondary parkinsonism |
| |
| G21.11 |
|
Neuroleptic induced parkinsonism |
| |
|
| | |
| G21.19 |
|
Other drug induced secondary parkinsonism |
| |
| Other medication-induced parkinsonism |
| UseAdditionalCode |
code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
|
|
| |
| |
| G21.2 |
|
Secondary parkinsonism due to other external agents |
| |
| CodeFirst |
(T51-T65) to identify external agent
|
|
|
| |
| G21.3 |
|
Postencephalitic parkinsonism |
|
| |
| G21.4 |
|
Vascular parkinsonism |
|
| |
| G21.8 |
|
Other secondary parkinsonism |
|
| |
| G21.9 |
|
Secondary parkinsonism, unspecified |
|